Mylan is still facing public outrage over its decision to jack up EpiPen prices, but a new report from the New York Times claims that Mylan’s chairman isn’t worried about the backlash at all.
According to business reporter Charles Duhigg, some executives within Mylan tried to warn Mylan Chairman Robert Coury about the dangers of moving too aggressively in hiking prices for EpiPen, and they were given a very rude response.
“In meetings, the executives began warning Mylan’s top leaders that the price increases seemed like unethical profiteering at the expense of sick children and adults, according to people who participated in the conversations,” Duhigg reports. “Mr. Coury replied that he was untroubled. He raised both his middle fingers and explained, using colorful language, that anyone criticizing Mylan, including its employees, ought to go copulate with themselves. Critics in Congress and on Wall Street, he said, should do the same.”
Mylan started coming under fire last year when it was revealed that it has raised the price of the life-saving EpiPen drug by 450 percent over the past 12 years. During that time, Mylan CEO Heather Bresch received massive increases in compensation, going $2.5 million in 2007 to $18.9 million in 2015.